EQL PHARMA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40 SEK | +0.76% |
|
-8.88% | +19.76% |
| Apr. 22 | EQL Pharma AB Announces Mellozzan Launched in Germany and Austria | CI |
| Feb. 13 | EQL Pharma AB Provides Sales Guidance for the Year 2023/24 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 313M 28.99M | Sales 2025 * | 426M 39.47M | Capitalization | 1.16B 108M |
|---|---|---|---|---|---|
| Net income 2024 * | 60M 5.56M | Net income 2025 * | 71M 6.58M | EV / Sales 2024 * | 4.05 x |
| Net Debt 2024 * | 104M 9.63M | Net Debt 2025 * | 85M 7.87M | EV / Sales 2025 * | 2.93 x |
| P/E ratio 2024 * |
19.3
x | P/E ratio 2025 * |
16.3
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.76% | ||
| 1 week | -8.88% | ||
| Current month | -7.83% | ||
| 1 month | -9.09% | ||
| 3 months | +5.26% | ||
| 6 months | +41.34% | ||
| Current year | +19.76% |
1 week
38.40
43.80
1 month
38.4046.00
Current year
33.0046.00
1 year
24.7046.00
3 years
23.0048.70
5 years
9.5048.70
10 years
2.8048.70
| Managers | Title | Age | Since |
|---|---|---|---|
Axel Schörling
CEO | Chief Executive Officer | 38 | 18-01-31 |
| Founder | 59 | 05-12-31 | |
Anna Jönsson
DFI | Director of Finance/CFO | 40 | 21-12-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 05-12-31 | |
| Director/Board Member | 64 | 14-12-31 | |
| Director/Board Member | 51 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 40 | +0.76% | 13,700 |
| 24-05-13 | 39.7 | -5.70% | 48,805 |
| 24-05-10 | 42.1 | -3.88% | 21,216 |
| 24-05-08 | 43.8 | -0.23% | 1,090 |
| 24-05-07 | 43.9 | -0.68% | 1,996 |
End-of-day quote NORDIC GROWTH MARKET, May 13, 2024
More quotes
EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.
Sector
Drug Retailers
Calendar
2024-08-12
- Q1 2025 Earnings Release (Projected)
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.76% | 107M | |
| -29.72% | 15.83B | |
| -22.89% | 12.31B | |
| -24.53% | 6.59B | |
| +15.23% | 6.45B | |
| -12.11% | 5.94B | |
| -1.90% | 4.66B | |
| +62.00% | 4.59B | |
| -5.94% | 3.96B | |
| -9.36% | 3.55B |
- Stock Market
- Equities
- EQL Stock